The Oxford-linked oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.

Immunocore, a UK-based immunotherapy developer that traces its origins to University of Oxford, has secured $75m in a series C round led by an unnamed returning investor.
The round included accounts and vehicles for investment management firm BlackRock as well as undisclosed existing backers. In addition, Oxford Finance supplied $100m in debt financing.
Immunocore is working on T-cell receptor (TCR)-based drugs, which introduce modified white blood cells in the immune system in a bid to fight infectious and autoimmune…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in